Prionelle

Prionelle is a combined oral contraceptive (COC) developed and marketed by CampusPharma, specifically for the Nordic markets. It is a fixed-dose combination product containing 150 micrograms of levonorgestrel (a second-generation progestogen) and 30 micrograms of ethinylestradiol (a synthetic estrogen). Prionelle works by suppressing the mid-cycle surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby inhibiting ovulation. It additionally increases the viscosity of cervical mucus to prevent sperm penetration and alters the endometrial lining to discourage implantation. Within the Nordic clinical guidelines, Prionelle is often recommended as a first-line contraceptive choice because levonorgestrel-containing combinations are associated with a lower risk of venous thromboembolism (VTE) compared to those containing third- or fourth-generation progestogens.

Brand names

PrionellePrionelle 28Prionelle28Prionelle-28

Other names

levonorgestrel + ethinylestradiol